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Because of the limitations and invasive nature of liver biopsy, other noninvasive 
means are being tested for the evaluation of diffuse liver diseases. One of these methods 
is vibration-controlled transient elastography (VCTE). This chapter reviews the princi-
ple of VCTE, the examination technique, the normal range for liver stiffness values, the 
pathological changes that may influence liver stiffness, as well as the diagnostic perfor-
mance in several diffuse liver diseases, especially chronic hepatitis C, chronic hepatitis 
B, nonalcoholic steatohepatitis, and alcoholic liver disease. Apart from the assessment 
of fibrosis stages, we will also discuss the diagnosis of cirrhosis and its complications as 
well as other applications of VCTE, reviewing its advantages and limitations.
Keywords: diffuse liver disease, fibrosis, noninvasive,  
vibration-controlled transient elastography, Fibroscan
1. Introduction
Chronic liver diseases are an important public health issue. Extensive research 
has been made lately on the development of noninvasive diagnostic methods, 
able to accurately assess fibrosis and steatosis. Among these, an important place is 
reserved for elastographic techniques and especially vibration-controlled transient 
elastography (Fibroscan).
2. Principle
Vibration-controlled transient elastography is performed with the 
Fibroscan® equipment (Echosens, Paris) [1]. The transducer of the device is 
placed in an intercostal space above the right liver lobe, in a point of maximal 
hepatic dullness. A mechanical vibrator is mounted on the axis of the device; the 
vibrator generates a painless vibration, inducing a train of elastic waves, which 
propagate through the skin and subcutaneous tissue to the liver. In parallel to 
the vibration, the transducer performs ultrasound acquisitions, at a frequency 
of 4 kHz [1–3] By comparing the ultrasonographic signals thus obtained, tissue 
deformation records, induced by the propagation of the elastic wave, can be 
drawn. The time necessary for the train of waves to propagate along the interest 
Ultrasound Elastography
2
area, as well as the velocity of propagation, is recorded. The liver stiffness can 
afterwards be calculated using the formula: E = 3ρVs2 (E, the elasticity module; 
ρ, density; Vs, the elastic wave velocity in the liver parenchyma). The stiffer the 
tissue, the higher the velocity of the wave train [1–3].
On the other hand, knowing that fat impairs ultrasound propagation and 
induces attenuation, the producers of the Fibroscan equipment have developed 
a software able to precisely quantify the ultrasound attenuation. This controlled 
attenuation parameter (CAP) is expressed in dB/m and is calculated using the same 
radio-frequency data, and the same region of interest, as the region used to assess 
the liver stiffness [4, 5].
3. Examination technique
The patient is placed in a dorsal decubitus position, with the right arm in 
maximum abduction above the head, in order to best expose the right abdominal 
quadrant, perpendicularly to the intercostal space, in an area of maximal dull-
ness, free of any large vascular structure [1, 3]. When pressing the transducer 
button, the vibration is generated and transmitted to the liver. The software of the 
equipment analyzes the tissue deformation records and measures the stiffness of 
the parenchyma. The results are expressed in kilopascals (kPa) and represent the 
median value of 10 valid measurements. The equipment can measure values rang-
ing between 2.5 and 75 kPa [1, 3]. At the same time, the software can measure both 
the liver stiffness (for the assessment of fibrosis) and the controlled attenuation 
parameter, CAP (for the assessment of steatosis).
It is important to choose the correct transducer for the examinations (S, M, or 
XL). The choice is made according to the circumference of the thorax: if below 
75 cm, the S probe is chosen (either S1 < 45 cm or S2 for 45–75 cm and the M probe 
for a thoracic circumference above 75 cm). The XL transducer will be chosen if the 
distance between the skin and the liver capsule exceeds 25 mm. It is worth mention-
ing that, when measured with the XL probe, the median liver stiffness is signifi-
cantly lower than that measured with the M probe [6].
The examination should be performed after an overnight fast, or at least 2 hours 
after a meal, because a postprandial examination would raise the stiffness value 
due to increased hepatic blood flow [7, 8]. In addition, the patient should remain at 
rest for 10 minutes before the examination [9] and hold his or her breath during the 
examination [10].
A proper measurement can be performed even by a technician after a training 
period (approximately 100 cases) [6, 10], but the clinical interpretation of results 
must always be issued by an expert taking into account the demographic data, 
disease etiology, and biochemical profile at the moment of the examination [3, 11].
Following the manufacturer’s recommendation, the assessment is reliable only 
when 10 valid readings and an IQR ≤ 30% of the median (IQR/M ≤ 30%) are 
obtained [9].
4. Normal range of liver stiffness
The mean value of liver stiffness in healthy subjects, without any known 
liver disease and with normal biochemistry and hematology tests, is 5.5 ± 1.6 kPa 
according to some authors [12] and 4.8 ± 1.3 kPa according to others [13]. Age 
does not appear to influence this value, but stiffness is higher in men than in 
women (5.8 ± 1.6 kPa vs. 5.2 ± 1.6 kPa) as well as in subjects with a BMI > 30 kg/m2 
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(6.3 ± 1.9 kPa vs. 5.4 ± 1.5 kPa) [14]. It is very difficult to establish the normal range 
of liver stiffness without biopsy, but the reverse is not feasible. In a group of HCV 
patients, without pathological changes on the biopsy sample, the liver stiffness was 
4.84 ± 1.49 kPa [15]. In our unit, values of or above 5.3 kPa have a positive predictive 
value of 90% for the prediction of a fibrosis stage of at least F1.
5. Pathological changes influencing liver stiffness
Although liver stiffness correlates very well with fibrosis, just a single physical 
parameter (stiffness) cannot be used to completely describe a complex biological 
system, in which fibrosis is just a part [2]. Liver stiffness is increased by hepatic 
inflammation (often but not exclusively revealed by an elevated transaminase level) 
[16–18], obstructive cholestasis [19], hepatic congestion [20], amyloidosis, lympho-
mas, and extramedullary hematopoiesis [9]. These error factors must be taken into 
consideration when interpreting the liver stiffness values.
Necroinflammatory activity leads to an increase in liver stiffness alongside the 
degree of histologic activity [21–23]. For instance, the tissue changes occurring 
during an acute hepatitis can associate a rise in liver stiffness reaching sometimes 
cirrhotic values, due to cellular intumescence and sometimes to severe cholestasis 
[24]. The contribution of these non-fibrotic alterations on stiffness has been dem-
onstrated by recording the progressive decrease in stiffness alongside the decrease 
in transaminase levels [17, 18]. On the other hand, in patients with relapsed chronic 
hepatitis, the higher stiffness values are caused not only by pre-existing fibrosis but 
also to the superimposed cellular intumescence [16]. Therefore, caution is advised 
when interpreting the liver stiffness values in patients with increased ALT: if the 
ALT values exceed a 2.5-fold increase, there is a risk of overestimating the fibrosis 
stage which should be specified in the written report [15].
Extrahepatic cholestasis can increase the stiffness independently from fibrosis 
[19], and after biliary drainage, the liver stiffness values decrease at a mean rate 
of 1.2 ± 0.56 kPa for every 1 g/dL decrease in bilirubin levels. It would therefore 
be prudent to exclude a possible cholestasis through imaging and lab tests before 
interpreting liver stiffness values in order to avoid overestimating the fibrosis stage.
Congestive heart failure may lead to increased liver stiffness reaching even cir-
rhotic levels, due to a higher liver blood volume, in up to 60% of patients [25–27].
Liver steatosis influence on liver stiffness values remains controversial. In some 
studies, steatosis did not significantly affect stiffness values, even after adjust-
ing for fibrosis stage, but the proportion of patients with severe steatosis was too 
low to allow accurate quantification of a potential influence [1, 21, 28]. Other 
studies, however, have proven that, for the same fibrosis stage and the same 
 necroinflammation grade, the presence of steatosis leads to a significant increase in 
liver stiffness [29]; furthermore, the morphometric analysis of biopsy samples has 
proven that steatosis does change liver stiffness independently from fibrosis. This 
influence is negligible in cirrhotic patients, but significant in non-cirrhotic patients. 
Further studies are however required to clarify this issue [28].
6. Diagnostic performance of VCTE
6.1 Chronic hepatitis C (CHC)
The first patients to have benefited from vibration-controlled transient elastogra-
phy were those diagnosed with chronic C viral hepatitis (HCV). Studies performed 
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on large groups of HCV patients indicate that the liver stiffness values are strongly 
correlated with fibrosis stage, but there is some degree of overlap between adjacent 
stages. The practical utility of the method is based on establishing certain threshold 
stiffness values for each fibrosis stage. The diagnosis of stages F ≥ 2, F ≥ 3, and 
cirrhosis is based on the following stiffness values: 5.2–9.5 kPa, 9.5–9.6 kPa, and 
11–15 kPa, respectively, as proposed by certain studies [15, 21, 30–34]. As sug-
gested by studies assessing other noninvasive methods [35], the difference between 
these values can be explained by the varying prevalence of each fibrosis stage in 
the analyzed groups as well as by the different aims of the investigation (screening 
strategy vs. exclusion strategy). Therefore, although the already-defined cutoffs may 
be relevant to a certain population, they may not be applicable in another population 
with different prevalence of fibrosis stage and with another diagnostic aim for per-
forming VCTE. In any case, according to the EFSUMB guidelines, “TE can be used as 
the first-line assessment for the severity of liver fibrosis in patients with chronic viral 
hepatitis C. It performs best with regard to the ruling out of cirrhosis” [9].
6.2 Chronic hepatitis B (CHB)
In patients with CHB, VCTE has a similar performance as in CHC patients 
[9]. For this type of patients, Marcellin and collaborators [36], considering the 
METAVIR scoring system, have suggested as early as 2009 the 7.2 kPa stiffness value 
as the cutoff for the prediction of F ≥ 2 (Se 70%, Sp 83%, PPV 80%, NPV 73%, 
AUROC 0.81), 8.1 kPa for F ≥ 3 (Se 86%, Sp 85%, PPV 65%, NPV 95%, AUROC 
0.93), and 11 kPa for the prediction of cirrhosis (Se 93%, Sp 87%, PPV 38%, NPV 
99%, AUROC 0.93).
Other articles [37–42] have confirmed the performance of the method, yield-
ing AUROC values raging between 0.80 and 0.90 (for the prediction of significant 
fibrosis) and liver stiffness cutoffs varying between 6.6 and 8.8 kPa [9, 43–47]. With 
regard to the prediction of cirrhosis, AUROCs vary between 0.81 and 0.97 and the 
cutoffs between 9.4 and 13.4 kPa [44, 45]. The meta-analyses have suggested that a 
liver stiffness above 11.7 kPa should raise the suspicion of cirrhosis in patients with 
CHB [9, 45].
Generally, the cutoff value used for the cirrhosis prediction is lower in CHB 
than in CHC patients. One explanation could be the fact that HBV infection is one 
of the causes of macronodular cirrhosis, so that the predominant macronodular 
regeneration and the fine fibrous septa surrounding the nodules mean a smaller 
quantity of fibrosis than in micronodular cirrhosis with thick fibrous septa. It fol-
lows that, generally, liver stiffness is lower in macronodular than in micronodular 
cirrhosis.
On the other hand, liver stiffness values below 5 kPa in patients with normal 
ALT and low serum HBV DNA levels (<2000 IU/ml) are characteristic for inactive 
HBV carriers [9, 48, 49]. VCTE can be used to rule out significant fibrosis and cir-
rhosis in HBV inactive carriers, which is the best indication for VCTE in HBV.
According to the EFSUMB guidelines, “TE is useful in patients with CHB 
to identify those with cirrhosis, but concomitant assessment of transaminases 
is required to exclude flare-ups (elevation > 5 times upper limit of normal)”. In 
addition, TE is useful in inactive HBV carriers to rule out fibrosis, in case the liver 
stiffness is below 5 kPa [9].
6.3 Nonalcoholic steatohepatitis (NASH)
In NASH patients, the correlation between stiffness and fibrosis is weaker than 
in patients with chronic viral hepatitis, because of a different fibrosis distribution 
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pattern (in chronic viral hepatitis, fibrosis appears early in the periportal areas and 
gives rise to a dense, stellate, and regularly distributed portal fibrosis; in steatohep-
atitis, however, the fibrosis is located in the perisinusoidal space of the centrilobular 
area and in the walls of the centrilobular vein) [28, 50]. There is a direct proportion 
between the amount of dense, stellate portal fibrosis and liver stiffness, whereas 
perisinusoidal fibrosis distributed preferentially in the centrilobular areas does not 
proportionally increase the liver stiffness values, as was proven by morphometric 
studies [28].
A meta-analysis including 854 NASH patients examined with the M probe [51] 
has proven the very good performance of VCTE in diagnosing stages F ≥ 3 (Se 82%, 
Sp 82%) and F4 (Se 92%, Sp 92%) and its moderate performance in diagnosing 
significant fibrosis F ≥ 2 (Se 79%, Sp 75%). The cutoff yielded by various studies 
varies between 6.6 and 7.7 kPa (for F ≥ 2), 8–10.4 kPa (for F ≥ 3), and 10.3–17.5 kPa 
(for the prediction of cirrhosis) [50, 52–57].
The available data indicate that, in patients with NAFLD, VCTE is a highly accu-
rate, noninvasive method for the exclusion of advanced fibrosis and a moderately 
accurate method for the exclusion of significant fibrosis. According to the EFSUMB 
and EASL Guidelines and Recommendations on the clinical use of liver ultrasound 
elastography, “TE can be used in NAFLD patients to confidently exclude severe 
fibrosis and especially cirrhosis,” with a high negative predictive value (around 
90%) [9, 34].
6.4 Alcoholic liver disease (ALD)
There is no consensus regarding the optimal cutoffs for the prediction of fibrosis 
stages in ALD patients [9, 58]. In various studies, the cutoffs range between 7.8 and 
9.6 kPa for significant fibrosis, 8.0–17.0 kPa for severe fibrosis, and 7.15–34.9 kPa 
for cirrhosis prediction; the explanation for this variation lies in the difference 
in prevalence of fibrosis stages in the analyzed groups, as well as in the different 
patient selection methods (with or without exclusion of acute alcoholic hepatitis or 
of patients with decompensated disease) [59–62].
In a meta-analysis by Pavlov, the cutoffs used for the prediction of fibrosis stages 
were the following: 5.9 kPa for ≥F1 (Se 83%, Sp 86%, PPV 97.6%, NPV 35.3%, and 
AUROC 0.84), 7.5 kPa for ≥F2 (Se 94%, Sp 89%, positive likelihood ratio 8.2, nega-
tive likelihood ratio 0.07), and 9.5 kPa for ≥F3 (Se 92%, Sp 68%, positive likelihood 
ratio 2.9, negative likelihood ratio 0.11) [63]. For the prediction of cirrhosis, the 
proposed 12.5 kPa cutoff had a 95% sensitivity and 71% specificity, a 3.3 positive 
likelihood ratio, and a 0.07 negative likelihood ratio [63].
The proposed cutoff values for the different stages of hepatic fibrosis may be 
used in clinical practice, but with caution, since those reported values were simply 
the most common cutoff values used by the study authors and are insufficiently 
validated while, additionally, there is always the risk of overestimation of LS values 
in patients who are not abstinent from alcohol consumption.
It is also important to consider the AST levels when using VCTE to assess fibrosis 
in ALD patients. For AST levels above 100 U/L, the liver stiffness may increase 
independently from fibrosis, as a result of steatohepatitis, leading to interpretation 
errors [59]. On the other hand, liver stiffness decreased significantly after alcohol 
cessation over a long period of follow-up. It follows that liver stiffness measure-
ments in alcoholic liver disease should be interpreted with caution and assessed in 
regard to the current alcohol consumption. Large-scale prospective studies should 
be performed to determine the different optimal cutoff values according to alcohol 
consumption, and more data are required to determine the best delay after alcohol 
cessation prior to VCTE evaluation.
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VCTE is more suited to rule out than to rule in cirrhosis. At a Young’s modulus of 
12.5 kPa, VCTE may rule out cirrhosis with a negative likelihood ratio of 0.07 if the 
disease prevalence is 50% or lower.
In conclusion, according to the EFSUMB guidelines, “TE can be used to exclude 
cirrhosis in patients with alcoholic liver disease, provided that acute alcoholic 
hepatitis is not present” [9]. The current alcohol drinking status is also relevant.
6.5 Other chronic liver diseases
The performance of VCTE in identifying significant fibrosis was also assessed in 
other chronic liver diseases, such as HCV-HIV coinfection [64, 65], post liver trans-
plantation status [66–69], cholestatic liver diseases (primitive biliary cirrhosis or 
primary sclerosing cholangitis) [70], and hemochromatosis [71]: the results yielded 
AUROC values between 0.74 and 0.93 for the prediction of significant fibrosis, at 
cutoffs ranging between 4 and 10.1 kPa.
6.6 The diagnosis of cirrhosis and its complications
One of the most important applications of VCTE is the noninvasive diagnosis of 
liver cirrhosis. The diagnostic accuracy of VCTE is far better in the prediction of cir-
rhosis than that of other stages of fibrosis, with areas under the ROC curve (AUROCs) 
ranging between 0.90 and 0.99 at cutoffs between 9 and 26.6 kPa. In a meta-analysis 
performed by Friedrich-Rust [72], the mean AUROC for the diagnosis of cirrhosis 
was 0.94, and the optimal cutoff for cirrhosis prediction proved to be 13.01 kPa. In 
Stebbing’s meta-analysis [73], the 15.08 kPa cutoff had 84.45% sensitivity and 94.69% 
specificity for the prediction of cirrhosis. Tsochatzis [74] assessed the diagnostic 
accuracy of VCTE in the prediction of cirrhosis in a meta-analysis of 30 studies, which 
yielded a LS optimal cutoff of 15 ± 4.1 kPa (median, 14.5 kPa, ranging between 9 and 
26.5 kPa in the various studies analyzed), with 83% sensitivity and 89% specificity. It 
is however important to keep in mind that the cutoffs proposed by the various studies 
were chosen based on the AUROCs providing the maximal sum between sensitivity 
and specificity. As was suggested in certain studies performed for the assessment of 
other noninvasive methods, the difference between these values can, however, be 
explained by the difference in prevalence of cirrhosis in the analyzed groups [35].
On the other hand, interpreting the LS value as compatible with the diagnosis 
of cirrhosis can only be made after excluding some other conditions: significant 
cytolysis, significant cholestasis, right heart failure, or performing the examina-
tion after a meal. Nevertheless, even if the liver stiffness values are not typical 
for cirrhosis, cirrhosis may however be present in 3% of cases. This is the case of 
macronodular cirrhosis (more frequent in HBV infection, but also in other liver 
diseases) where the nodules are surrounded by fine fibrous septa, which do not 
increase the liver stiffness to “cirrhotic” levels.
6.6.1 Portal hypertension screening
Various studies have reported on the correlation between the LS value and portal 
hypertension (PHT), identified either through the presence of esophageal varices 
(EV) during upper digestive endoscopy [75–77] or by measuring the hepatic venous 
pressure gradient (HVPG), considered the gold standard in the assessment of portal 
hypertension [66, 77–79].
Despite an excellent correlation at HVPG values below 10 or 12 mm Hg, the 
comparison did not yield valuable results at HVPG values > 10 mm Hg (which is 
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the HVPG threshold for the prediction of varices) or > 12 mm Hg (threshold for the 
prediction of other complications, such as variceal effraction or ascites).
When analyzing the relationship between liver stiffness and the presence of 
esophageal varices, the area under the ROC curve for the prediction of varices 
varied between 0.74 and 0.85. When using the 13.9 kPa, 17.6 kPa, and 21.3 kPa 
cutoff values, the authors found high sensitivity for the prediction of varices 
(95%, 90%, and 79%, respectively) but relatively low specificity (43, 43, and 
70%, respectively) [3, 75–77].
Some authors claim that there is a correlation between liver stiffness values 
and variceal size [75, 76, 78], while others could find no proof of this correlation 
[77]. For the prediction of grade 2 and 3 varices, TE had a high sensitivity  
(91% and 76%) at the 19 kPa and 30.5 kPa cutoffs, respectively, but with low speci-
ficity (60% and 80%, respectively) and positive predictive value (48% and 54%,  
respectively) [75, 76].
According to the Baveno VI criteria [80], in patients with compensated chronic 
liver diseases of viral etiology, the noninvasive methods may predict the clinically 
significant portal hypertension, identifying the proportion of patients at risk of 
having endoscopic markers of PHT. For that purpose, liver stiffness measurements 
above 20–25 kPa can be used alone or in combination with platelet levels and spleen 
size. Liver stiffness below 20 kPa and platelet levels above 150,000 indicate a very 
low risk of esophageal varices requiring treatment, and therefore endoscopic 
screening can be avoided. These patients must be followed-up annually (VCTE and 
platelet levels), and an endoscopy must be performed in case of increasing stiffness 
or decreasing platelets.
The assessment of spleen stiffness has emerged as a new technique in hepatol-
ogy, which may provide useful information on the presence and degree of portal 
hypertension and the prediction of its complications.
6.6.2 Prognostic significance of LS in patients with liver cirrhosis
Some studies suggested that VCTE could be used as a risk marker for the 
development of a hepatocarcinoma in patients with hepatitis C [81, 82], who have 
a fivefold increase in risk at liver stiffness values above 25 kPa. On the other hand, 
in our experience, in patients with hepatitis C-related cirrhosis, a liver stiffness 
value > 38 kPa and an IQR > 30% of the median value (after previous exclusion of 
gross technical errors) are important markers which suggest the need for further 
imaging investigations in search of a possible hepatocarcinoma (HCC) [83]. Some 
authors have found that an increase in LS of more than 1 kPa at 3 years is cor-
related with a worse prognosis and with an increase in mortality rate in the next 
2 years; for every 1 kPa increase over the median LS found in any given patient, 
the relative risk for a severe clinical event in that particular patient increases: 1.07 
for hepatic decompensation, 1.11 for HCC, and 1.22 for death [84]. Nevertheless, 
these results require confirmation through prospective studies performed on large 
groups of patients, in order to confirm whether liver stiffness can indeed predict 
complications in decompensated cirrhosis [11]. In case it does, elastography may 
serve as a method of fast noninvasive screening, in order to classify each patient 
in a risk category [85].
6.7 Other applications of VCTE
The assessment of liver stiffness using VCTE is useful in the monitoring of 
adverse effects of hepatotoxic medication [86] as well as that of the effect of 
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antiviral therapy. Of course, in the latter situation, it is difficult to establish with 
certainty to what extent the decrease in liver stiffness is caused by a regression in 
fibrosis, a stabilization of necroinflammation, or both: however, a decrease in LS 
values in parallel with antiviral treatment exhibited favorable short- and long-term 
outcomes in patients with chronic viral hepatitis.
7. Advantages of VCTE
The technique is easy to use, painless, noninvasive and does not require hos-
pitalization. It can measure at the same time liver stiffness (for the prediction of 
 fibrosis) and the controlled attenuation parameter (CAP) for the prediction of 
steatosis, in a volume 100 times larger than that examined during a liver biopsy.
8. Limitations of VCTE
Liver fibrosis cannot be evaluated by VCTE in 5–8% of the cases [3], especially in 
the case of obesity, ascites, or narrow intercostal spaces. In the case of obesity, using 
the XL probe helps to lower the measurement failure. The measurement failure is 
significantly less frequent when using the XL probe than the standard M probe [54]. 
The XL probe can still yield unreliable results, but only in 25%, as opposed to 50% 
of cases with the M probe [87]. The main limiting factors for the XL probe are a 
skin-to-liver capsule distance > 3.4 cm and extreme obesity (BMI > 40 kg/m2) [54].
9. Conclusions
In conclusion, vibration-controlled transient elastography (VCTE) is a useful 
method in the assessment and monitoring of diffuse liver diseases. It is important to 
perform the technique correctly and to interpret the results considering the clinical 
context, disease etiology, and laboratory results.
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